Kaplan Fox & Kilsheimer LLP Alerts Microvast Holdings, Inc. (NASDAQ: MVST) Investors to the Lead Plaintiff Deadline on September 21, 2026

A securities class action alleges Microvast overstated its ability to meet margin targets and complete its Huzhou Phase 3.2 manufacturing expansion by year-end 2025. The complaint cites Microvast's March 16, 2026 disclosure of quarterly gross margin collapsing to about 1% from roughly 36% a year earlier, alongside $96.5 million of quarterly revenue, down 15% year over year. The lawsuit follows allegations of operational, inventory-management, and customer rollout issues, creating material legal and credibility risks for MVST investors.

Analysis

The actionable issue is not the plaintiff filing itself—these notices rarely alter enterprise value—but the underlying combination of inventory impairment, weak utilization, and delayed customer ramps. For MVST, a near-breakeven gross-margin quarter implies that fixed manufacturing costs are not being absorbed; unless utilization recovers materially, additional pricing concessions or inventory write-downs could keep gross margin structurally below management’s prior targets through the next 2-4 quarters. This raises financing risk: a company funding capacity while cash conversion deteriorates can face dilution well before litigation reaches a meaningful resolution.

The second-order read-through is negative for smaller, China-linked battery suppliers with concentrated commercial-vehicle/ESS customers, while scaled cell manufacturers such as CATL, BYD, LG Energy Solution, Panasonic and Samsung SDI can use lower-cost capacity and stronger balance sheets to win delayed programs. Customers may also dual-source or demand tighter acceptance and warranty terms, shifting working-capital burden onto weaker suppliers. The disclosed South Korean regulatory sensitivity is a reminder that project-based ESS demand can be discontinuous rather than a smooth secular-growth curve.

Near term, avoid treating the lead-plaintiff deadline as a catalyst; it is procedural and likely immaterial. The investable catalysts over 1-3 months are evidence of further inventory reserves, cash-burn acceleration, a delayed or reduced capacity plan, auditor/internal-control commentary, or a capital raise. Over 6-18 months, the thesis turns only if verified utilization, backlog conversion, and gross-margin recovery demonstrate that the impairment was isolated rather than evidence of a recurring product/customer-quality problem.

Contrarian risk is that most of the operational damage may already be reflected following the prior disclosures, making an outright short vulnerable to low-float volatility, subsidy/policy headlines, or a single large order announcement. A durable reversal requires more than revenue growth: monitor operating cash flow and gross margin excluding reversals/one-time items. Sustained double-digit gross margin with positive working-capital conversion would falsify the bearish operating thesis.

Key Decisions for Investors

• Do not initiate a position solely on the lawsuit notice; treat it as confirmation of elevated disclosure risk, not a new fundamental catalyst.
• For existing MVST exposure, reduce or hedge into any litigation-driven bounce over the next 1-3 months; retain exposure only if the next results show improving gross margin and operating cash flow rather than merely backlog commentary.
• If borrow is available and liquidity is adequate, consider a small tactical MVST short only after a failed rally on earnings/capital-plan updates; cover if management delivers two consecutive quarters of double-digit gross margin and materially improved cash conversion.
• Prefer a relative-value expression: long diversified battery leaders with proven scale (BYDDY or a sector proxy such as LIT) versus short MVST, sized modestly for idiosyncratic squeeze risk. The trade works if customer qualification and project delays shift share toward stronger balance sheets over 6-18 months.
• Set alerts for incremental impairment charges, equity/debt financing, auditor or internal-control disclosures, and any revision to production-capacity timing; each would increase dilution and multiple-compression risk.